The product, called CytoSurge 3D fibre scaffold, has applications in cell research, biopharmaceuticals, cell therapeutics, and cultured meat and seafood development
University of Georgia startup CytoNest Inc. released its first commercial product, a fibre scaffold that optimises cell manufacturing and tissue engineering, last month.
The product, called CytoSurge 3D fibre scaffold, has applications in cell research, biopharmaceuticals, cell therapeutics, and cultured meat and seafood development.
UGA is ranked No. 1 among U.S. universities for several commercial products to market based on its research, according to an annual survey conducted by AUTM. The university has seen over 1,200 products make it to market.
“Congratulations to CytoNest on launching their first product and adding to UGA’s legacy of translating research discoveries into products,” said Derek Eberhart, UGA’s associate vice president for research and executive director of Innovation Gateway, UGA’s technology transfer organisation. “For the past eight years, UGA has ranked either first or second among U.S. universities for new products brought to the market by companies like CytoNest.”
Nataraja Yadavalli and Sergiy Minko, CEO and CSO of CytoNest, respectively, are the minds behind the new product, an edible fibre-based scaffold safe for living tissues that provides a point of contact for cells to adhere to and grow three-dimensionally in high densities. This provides a scaleable solution to those working on cultivated meat and seafood.
